ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

New Science Destroys the Saturated Fat Myth

Ginger's Many Evidence-Based Health Benefits Revealed

Diet Affects Men’s and Women’s Gut Microbes Differently

New Lyme guidelines promote options and informed choice

Natural products from plants protect skin during cancer radiotherapy

Dangers of desert dust: new diagnostic tool for valley fever

Phases of clinical depression could affect treatment

“Worm pill” could ease autoimmune disease symptoms

Eating Baked or Broiled Fish Weekly Boosts Brain Health, Pitt Study Says

The Effect of d-Lenolate® on the Immune Parameters in Humans

 
Print Page
Email Article

Opioids may encourage cancer; opioid antagonists may suppress

  [ 119 votes ]   [ 4 Comments ]
www.ProHealth.com • March 28, 2012


"Opioids appear to have a significant and direct proliferative effect on cancer cells.

The suspicion that opioid drugs for pain could encourage cancer growth began with a laboratory report from the University of Minnesota in 2002. Then at the University of Chicago, cancer patients in clinical trials of the opioid-blocker methylnaltrexone - a form of naltrexone(1) developed to reverse opioid side effects such as itching & constipation without affecting pain relief - began living longer than expected.

Something important was going on, and research teams at Chicago and the University of North Carolina pursued it to the conclusion that opioid drugs used to relieve pain in postoperative and chronic cancer patients may indeed stimulate the growth and spread of tumors. (While opioid antagonists may suppress it.)

As reported in a suite of free-access articles published in the April issue of Anesthesiology,(2,3,4) "Epidemiologic findings suggest that the type of anesthesia we do for cancer surgery influences recurrence rate, and laboratory studies demonstrate that opioids influence tumor progression and metastasis," says U Chicago co-author Jonathan Moss, MD, PhD.

"These studies have caused anesthesiologists to re-evaluate how best to do anesthesia and pain control for cancer patients."

New Studies Provide New Clues

Opioid-based painkillers, such as morphine, have been the gold standard for treatment of postoperative and chronic cancer pain for 200 years. Several studies published since 2002, however, suggest that opioids can stimulate the growth and spread of cancer cells.

Laboratory research from the University of Chicago Medicine and a genetic study from the University of North Carolina Medical Center both argue that the mu-opioid receptor (mu refers to morphine) plays an important role in tumor progression, and support a therapeutic role for opioid antagonists.

Cancer Cells Have 5 to 10 Times More Opioid Receptors than Normal Cells

A study led at Chicago by Prof Patrick Singleton, PhD,(4) shows how opioids already present in the body can enhance the malignant tendencies of human lung cancer cells transplanted into mice, even without the addition of morphine.

Dr. Singleton’s team found that cells from various types of human lung cancers have 5 to 10 times as many opioid receptors as non-cancerous lung cells.

• They mapped out two of the biochemical pathways - Akt and mTOR, both targets for current chemotherapeutics - that are triggered by contact between the body's endogenous opioids and the receptors.

• They also show how this interaction can increase proliferation, migration and invasion of tumor cells, three hallmarks of cancer growth and spread.

• And they found that human lung cancer cells with additional copies of the opioid receptor grew more than twice as fast as tumor cells that lacked extra receptors when transplanted into mice.

More troubling, the cancer cells were 20 times more likely to spread to distant sites.

Medications that block the opioid receptors, such as naloxone or methylnaltrexone, reduced tumor growth and spread. "Our findings," they conclude, "suggest the mu opioid receptor may be a therapeutic target."

Genetic Mutation for Poor Opioid Sensitivity is Protective

The retrospective study by Andrey Bortsov, MD, PhD, and colleagues at the University of North Carolina(2) used human data to bolster the opioid-cancer link. Dr. Bortsov's team looked at survival rates from an earlier study of more than 2,000 breast cancer patients.

Women being treated for invasive breast cancer who had a tiny genetic mutation that made them less sensitive to opioids were much more likely to be alive 10 years after cancer treatment.

• Women with one copy of the protective mutation were nearly twice as likely to have survived;

• Those with two copies were four times as likely to have survived 10 years.

"The results of this study," the authors wrote, "provide support for the hypothesis that endogenous and/or exogenous opioids, acting via the mu opioid receptor, may influence cancer outcomes."

Higher Cancer Risk if Opioid Medication is Systemic

The suspicion that opioids might encourage cancer growth arose with a 2002 laboratory report from the University of Minnesota.

• Later, a randomized palliative-care trial from Virginia Commonwealth University found that patients who received spinal opiates (OK) rather than systemic pain relief survived longer.

• Then two retrospective studies showed that breast or prostate cancer patients who received local or regional anesthesia rather than systemic morphine had improved survival after surgery.

• More recent epidemiologic studies in colon cancer, however, failed to confirm the relationship.

Methylnaltrexone Trials Took It to the Next Level

Dr. Moss and colleagues at Chicago approached the issue from a similar angle. They were involved in clinical trials of methylnaltrexone, a drug developed at Chicago and approved by the FDA in 2008.(3)

This drug, marketed as Relistor™, was designed to block the peripheral side effects of opioids, such as nausea and constipation, without disrupting pain relief, which occurs in the brain. (By comparison the opioid-blocking drug naltrexone crosses the blood-brain barrier.) Following an early clinical study, Dr. Moss and colleagues noted that cancer patients receiving this peripheral opioid blocker in a compassionate-use protocol lived longer than expected.

"These were patients with advanced cancer and a life expectancy of one to two months," Dr. Moss recalls, "yet several lived for another five or six months. It made us wonder whether this was just a consequence of better GI function, or could there possibly be an effect on the tumors?"

They began a series of studies looking at the many peripheral effects of opioids and the potential benefits of blocking those effects.

• They found that those opioids enhanced tumor growth, angiogenesis, vascular permeability and metastasis.

• Drugs that blocked the opioid receptor reduced cancer growth and helped prevent invasion and metastasis.

• Tumors did not grow in mice that lacked the mu opioid receptor.

In commenting on their findings, Dr. Moss, Dr. Singleton and Dr. Frances Lennon, PhD,(4) summarize results from multiple studies to argue that opioids - drugs like morphine or the body's own opioids, such as endorphins - appear to have a significant and direct proliferative effect on cancer cells, aside from their effect suppressing immunity.

They suggest a possible therapeutic role for mu opioid receptor antagonists on cancer growth and metastasis, but caution that "there are no clinical trials in humans demonstrating a direct effect."

Funding and Investigator Interests

Funding for the studies was provided by the National Cancer Institute, the University of North Carolina and the University of Chicago. Dr. Moss, one of the developers of methylnaltrexone, receives royalties from its sale and is a paid consultant for its distributor, Salix Pharmaceuticals Inc.

___

Source: Based on University of Chicago Medical Center news release, Mar 20, 2012 and American Society of Anesthesiologists news release, Mar 21, 2012

1. Unlike naltrexone, which crosses the blood-brain barrier, methylnaltrexone does not, so its activity does not affect pain processing in the brain and is confined to blocking opioid activity peripherally; e.g., in the GI tract. For more information on trials involving low-dose naltrexone therapy for fibromyalgia, chronic fatigue syndrome, and autoimmune diseases generally, see “Low-Dose Naltrexone for Autoimmune Diseases and Fibromyalgia?” by Dr. Joseph Mercola.

2. Full text: “Mu-Opioid Receptor Gene A118G Polymorphism Predicts Survival in Patients with Breast Cancer,” Bortsov AV, McLean S, et al.

3. Full text: “Overexpression of the mu-Opioid Receptor in Human Non-Small Lung Cancer Promotes Akt and mTOR Activation, Tumor Growth, and Metastasis,” Lennon FE, Moss J, et al.

4. Full text: “The mu-Opioid Receptor in Cancer Progression: Is There a Direct Effect?” Lennon FE, Moss J, Singleton PA.



Please Discuss This Article:   Post a Comment 

Zeta receptors and OGF
Posted by: r0xym0r0n
Mar 28, 2012
I would like to read some science that proves that endogenous opiods increase tumour cell proliferation. It has been proven that naltrexone and it's forms accelerate tumour growth and also that met-enkephalin does actually block tumour cell prolioferation - see Zagons work. I think that the methylnaltrexone here is actually stimulating the production of met enkephalin aka Opioid growth factor or OGF, and this acts on the zeta receptor, not the mu opioid receptor, to block the proliferation of tumour cells, This article is missing the point unfortunately, and should take a close look at all the papers published by Zagon and Penn state and others which prove this point. The zeta receptor effect is missed here, but do look into it to understand the way it works with OGF to block tumour cell proliferation. There are 4 endorphin class receptors, mu, lambda, kappa ad zeta and the zeta one is the important one here.
Reply Reply

OGF
Posted by: bwmbagus
Mar 28, 2012
I would like to read some science that proves that endogenous opiods increase tumour cell proliferation. It has been proven that naltrexone and it's forms accelerate tumour growth and also that met-enkephalin does actually block tumour cell prolioferation - see Zagons work. I think that the methylnaltrexone here is actually stimulating the production of met enkephalin aka Opioid growth factor or OGF, and this acts on the zeta receptor, not the mu opioid receptor, to block the proliferation of tumour cells, This article is missing the point unfortunately, and should take a close look at all the papers published by Zagon and Penn state and others which prove this point. The zeta receptor effect is missed here, but do look into it to understand the way it works with OGF to block tumour cell proliferation. There are 4 endorphin class receptors, mu, lambda, kappa ad zeta and the zeta one is the important one here.
Reply Reply

 
your proof, as requested
Posted by: cindytwo
May 20, 2012
http://www.asbmb.org/news.aspx?id=16944

 


Opium/opioids will suppress cancer tumor
Posted by: jeffwilson
Oct 17, 2012
The research of University Of Chicago by Dr. Moss should be reviewed very carefully. There is self interest involved here.Dr. Moss, one of the developers of methylnaltrexone, receives royalties from its sale and is a paid consultant for its distributor, Salix Pharmaceuticals Inc.Now Dr. Moss ,at University of chicago is the head of the researcher to advertise his product,methylnaltrexone to prove, it suppress and slow down the growth of cancer tumor in human body. Dr. Moss stated by his research that opiods drugs after surgery will encourage growth of tumor cancer. Dr Moss research & his data should be analized by a group of specialist very carefully.
For many years Opium & Opioids was believed to be the best drugs to slow down the growth of cancer cells. All researches proved to quit opium for older opium addicts will cause in growth of cancer tumor . Doctors were very hesitante to advise to older opium addicts ( over 65 or 70 years)to qiut their addictions concern for growth of cancerous cells in their body.

There has to be a center to fact check any researches from interest group for accurency of the data.

Reply Reply


Post a Comment

 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Immune Support Supplements

Featured Products

FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?
"It's Not Easy Being Green" - But It Is Healthy
Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Shoo Pain, Don't Bother Me - Top 10 Nutrients to Take Back Your Life Shoo Pain, Don't Bother Me - Top 10 Nutrients to Take Back Your Life
Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing